RU2138482C1 - Производные аминостильбазола или их гидраты, или их соли и фармацевтическая композиция на их основе - Google Patents

Производные аминостильбазола или их гидраты, или их соли и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2138482C1
RU2138482C1 RU96121800A RU96121800A RU2138482C1 RU 2138482 C1 RU2138482 C1 RU 2138482C1 RU 96121800 A RU96121800 A RU 96121800A RU 96121800 A RU96121800 A RU 96121800A RU 2138482 C1 RU2138482 C1 RU 2138482C1
Authority
RU
Russia
Prior art keywords
ethenyl
amino
phenyl
sulfonyl
carbon atoms
Prior art date
Application number
RU96121800A
Other languages
English (en)
Russian (ru)
Other versions
RU96121800A (ru
Inventor
Хидака Хиройоси
Мацуура Акира
Мацуда Масато
Original Assignee
Ниппон Синяку Ко., Лтд.
Хидака Хиройоси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ниппон Синяку Ко., Лтд., Хидака Хиройоси filed Critical Ниппон Синяку Ко., Лтд.
Publication of RU96121800A publication Critical patent/RU96121800A/ru
Application granted granted Critical
Publication of RU2138482C1 publication Critical patent/RU2138482C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
RU96121800A 1994-04-06 1995-04-05 Производные аминостильбазола или их гидраты, или их соли и фармацевтическая композиция на их основе RU2138482C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPHEI-6/068252 1994-04-06
JP6825294 1994-04-06
PCT/JP1995/000658 WO1995027699A1 (en) 1994-04-06 1995-04-05 Aminostilbazole derivative and medicine

Publications (2)

Publication Number Publication Date
RU96121800A RU96121800A (ru) 1999-02-10
RU2138482C1 true RU2138482C1 (ru) 1999-09-27

Family

ID=13368389

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96121800A RU2138482C1 (ru) 1994-04-06 1995-04-05 Производные аминостильбазола или их гидраты, или их соли и фармацевтическая композиция на их основе

Country Status (14)

Country Link
US (1) US5972976A (enExample)
EP (1) EP0754682B9 (enExample)
JP (1) JP3080405B2 (enExample)
KR (1) KR100293867B1 (enExample)
CN (1) CN1053658C (enExample)
AT (1) ATE207057T1 (enExample)
CA (1) CA2187214C (enExample)
DE (1) DE69523298T2 (enExample)
DK (1) DK0754682T3 (enExample)
ES (1) ES2165911T3 (enExample)
PT (1) PT754682E (enExample)
RU (1) RU2138482C1 (enExample)
TW (1) TW308586B (enExample)
WO (1) WO1995027699A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2282446C2 (ru) * 2001-04-10 2006-08-27 Ниппон Синяку Ко., Лтд. Лекарственное средство для хронического суставного ревматизма
EA007965B1 (ru) * 2002-04-11 2007-02-27 Авентис Фарма С.А. Способ получения комбретастатинов
RU2793411C1 (ru) * 2013-12-13 2023-04-03 Еврокем Агро Гмбх Смесь удобрений, содержащая ингибитор нитрификации
US11767273B2 (en) 2013-12-13 2023-09-26 Eurochem Agro Gmbh Fertilizer mixture containing nitrification inhibitor
US12060307B2 (en) 2017-02-01 2024-08-13 Eurochem Agro Gmbh Mixture containing 3,4-dimethylpyrazole and use thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824895T2 (de) * 1998-04-15 2005-06-30 Hidaka, Hiroyoshi, Nagoya Verfahren zur bestimmung des gens eines zielproteins mit hilfe eines medikamentes
WO1999058142A1 (en) * 1998-05-12 1999-11-18 Chen Wen Y Use of anti-prolactin agents to treat proliferative conditions
WO2000064875A1 (en) * 1999-04-23 2000-11-02 Nippon Shinyaku Co., Ltd. Method for pulvirizing to fine powder
US6521658B1 (en) 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
MXPA02005866A (es) * 1999-12-14 2002-10-23 Nippon Shinyaku Co Ltd Derivados de heterociclo y drogas.
JP2004359545A (ja) * 2001-03-08 2004-12-24 D Western Therapeutics Institute 抗癌剤耐性克服剤
WO2002087577A1 (en) * 2001-04-26 2002-11-07 Nippon Shinyaku Co., Ltd. Medicines
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
JP5149482B2 (ja) * 2002-09-06 2013-02-20 株式会社デ・ウエスタン・セラピテクス研究所 悪性腫瘍を処置するための医薬組成物、方法および使用
WO2006078941A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
US20100198262A1 (en) * 2009-01-30 2010-08-05 Mckinley Laurence M Axial offset bone fastener system
BR112015026048A2 (pt) 2013-04-19 2017-07-25 Univ Arkansas análogos de combretastatina
WO2015153635A1 (en) 2014-03-31 2015-10-08 Board Of Trustees Of The University Of Arkansas Disubstituted triazole analogs
CN112110829B (zh) * 2019-06-19 2023-08-01 复旦大学 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570594A1 (en) * 1991-12-10 1993-11-24 Shionogi & Co., Ltd. Hydroxamic acid derivative based on aromatic sulfonamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129611T2 (de) * 1990-08-20 1998-12-17 Eisai Co., Ltd., Tokio/Tokyo Sulfonamid-Derivate
JP2790926B2 (ja) * 1990-08-20 1998-08-27 エーザイ株式会社 スルホンアミド誘導体
JP2692467B2 (ja) * 1991-12-09 1997-12-17 ダイキン工業株式会社 空調制御装置の電力供給装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570594A1 (en) * 1991-12-10 1993-11-24 Shionogi & Co., Ltd. Hydroxamic acid derivative based on aromatic sulfonamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. - М.: Медицина, 1987, ч.2, с.428. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2282446C2 (ru) * 2001-04-10 2006-08-27 Ниппон Синяку Ко., Лтд. Лекарственное средство для хронического суставного ревматизма
EA007965B1 (ru) * 2002-04-11 2007-02-27 Авентис Фарма С.А. Способ получения комбретастатинов
RU2793411C1 (ru) * 2013-12-13 2023-04-03 Еврокем Агро Гмбх Смесь удобрений, содержащая ингибитор нитрификации
US11767273B2 (en) 2013-12-13 2023-09-26 Eurochem Agro Gmbh Fertilizer mixture containing nitrification inhibitor
US12060307B2 (en) 2017-02-01 2024-08-13 Eurochem Agro Gmbh Mixture containing 3,4-dimethylpyrazole and use thereof

Also Published As

Publication number Publication date
WO1995027699A1 (en) 1995-10-19
MX9604540A (es) 1997-09-30
JP3080405B2 (ja) 2000-08-28
ATE207057T1 (de) 2001-11-15
EP0754682B1 (en) 2001-10-17
US5972976A (en) 1999-10-26
KR970702253A (ko) 1997-05-13
EP0754682A1 (en) 1997-01-22
KR100293867B1 (ko) 2001-09-17
PT754682E (pt) 2002-03-28
EP0754682A4 (en) 1998-03-04
CN1145066A (zh) 1997-03-12
CA2187214A1 (en) 1995-10-19
TW308586B (enExample) 1997-06-21
DE69523298T2 (de) 2002-06-27
DK0754682T3 (da) 2002-02-04
ES2165911T3 (es) 2002-04-01
DE69523298D1 (de) 2001-11-22
CA2187214C (en) 2002-03-12
CN1053658C (zh) 2000-06-21
EP0754682B9 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
RU2138482C1 (ru) Производные аминостильбазола или их гидраты, или их соли и фармацевтическая композиция на их основе
US20230143751A1 (en) Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs
EP1474425B9 (en) Deazapurines and uses thereof
AU669520B2 (en) Pyrido(2,3-d)pyrimidine derivatives as phosphodiesterase inhibitors
TWI458723B (zh) １，２－雙取代雜環化合物
EP3271361B1 (en) Tricyclic heterocyclic compounds useful as inhibitors of tnf
JPWO1995027699A1 (ja) アミノスチルバゾール誘導体及び医薬
US6737424B2 (en) Alpha-substituted pyridazino quinoline compounds
CZ298805B6 (cs) Derivát arylalkanoylpyridazinu, zpusob jeho prípravy a farmaceutický prostredek, který ho obsahuje
PL119501B1 (en) Process for manufacturing novel,condensed pyrimidine derivatives pirimidina
EP2563792B1 (en) Imidazopyridazinyl compounds and their uses for cancer
AU621431B2 (en) Castanospermine esters in the inhibition of tumor metastasis
CN114269720B (zh) 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
JPS60149576A (ja) 坑炎症剤として有用な置換ヒドロキシ−２，３−ジヒドロベンゾフランおよびその類似体
JPS62252774A (ja) フタラジン誘導体およびその製造法
RU2248969C2 (ru) Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и противораковый агент
EP3328369A1 (en) Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
US20240262803A1 (en) Compounds, compositions and methods of treating disorders
JP2511709B2 (ja) キサントシリンｘモノメチルエ―テル誘導体及びそれを含有する抗腫瘍剤
IL41259A (en) 3-((4-methyl-1-piperazinyl carbonyl)oxy)-2-(2-quinolyl)-1-isoindoline derivatives,process for their preparation and pharmaceutical compositions containing the same
MXPA96004540A (en) Aminostilbazole derivative and medicine
IE43551B1 (en) Naphthyridine derivatives
GB2128190A (en) Chemical compounds
KR890004662B1 (ko) 1,8-나프티리딘과 1,5,8-아자나프티리딘 유도체 및 이의 제조방법
WO2004063336A2 (en) Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis